2 assets in Short Bowel Syndrome

Therapeutic assets addressing Short Bowel Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Glepaglutide Short Bowel Syndrome	Zealand Pharma	P3	B (60)
Crofelemer Short Bowel Syndrome	Napo Therapeutics, S.p.A.	P2	CCC (53)